Stemtech Stock Performance
| STEK Stock | USD 0.0005 0.0002 28.57% |
The entity has a beta of 3.9, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Stemtech will likely underperform. At this point, Stemtech has a negative expected return of -2.1%. Please make sure to validate Stemtech's treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if Stemtech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Stemtech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in March 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 133.1 K | |
| Free Cash Flow | -1.9 M |
Stemtech |
Stemtech Relative Risk vs. Return Landscape
If you would invest 0.34 in Stemtech on November 8, 2025 and sell it today you would lose (0.29) from holding Stemtech or give up 85.29% of portfolio value over 90 days. Stemtech is currently does not generate positive expected returns and assumes 14.4678% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Stemtech, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Stemtech Target Price Odds to finish over Current Price
The tendency of Stemtech OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0005 | 90 days | 0.0005 | about 85.34 |
Based on a normal probability distribution, the odds of Stemtech to move above the current price in 90 days from now is about 85.34 (This Stemtech probability density function shows the probability of Stemtech OTC Stock to fall within a particular range of prices over 90 days) .
Stemtech Price Density |
| Price |
Predictive Modules for Stemtech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Stemtech. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Stemtech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Stemtech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Stemtech is not an exception. The market had few large corrections towards the Stemtech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Stemtech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Stemtech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.07 | |
β | Beta against Dow Jones | 3.90 | |
σ | Overall volatility | 0.0009 | |
Ir | Information ratio | -0.14 |
Stemtech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Stemtech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Stemtech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Stemtech generated a negative expected return over the last 90 days | |
| Stemtech has high historical volatility and very poor performance | |
| Stemtech has some characteristics of a very speculative penny stock | |
| Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 64.0% of the company outstanding shares are owned by corporate insiders |
Stemtech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Stemtech OTC Stock often depends not only on the future outlook of the current and potential Stemtech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Stemtech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 37.6 M | |
| Short Long Term Debt | 1.1 M | |
| Cash And Short Term Investments | 828.2 K |
Stemtech Fundamentals Growth
Stemtech OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Stemtech, and Stemtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stemtech OTC Stock performance.
| Return On Asset | -0.75 | |||
| Profit Margin | (1.85) % | |||
| Operating Margin | (1.34) % | |||
| Current Valuation | 8.79 M | |||
| Shares Outstanding | 48.63 M | |||
| Price To Sales | 1.54 X | |||
| Revenue | 4.32 M | |||
| EBITDA | 1.58 M | |||
| Cash And Equivalents | 399.73 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 219.47 K | |||
| Book Value Per Share | (0.08) X | |||
| Cash Flow From Operations | (1.91 M) | |||
| Earnings Per Share | 0.10 X | |||
| Total Asset | 5.72 M | |||
About Stemtech Performance
By examining Stemtech's fundamental ratios, stakeholders can obtain critical insights into Stemtech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stemtech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Stemtech performance evaluation
Checking the ongoing alerts about Stemtech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Stemtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Stemtech generated a negative expected return over the last 90 days | |
| Stemtech has high historical volatility and very poor performance | |
| Stemtech has some characteristics of a very speculative penny stock | |
| Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 64.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Stemtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stemtech's stock is overvalued or undervalued compared to its peers.
- Examining Stemtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Stemtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stemtech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Stemtech's otc stock. These opinions can provide insight into Stemtech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.